Two forms of erythropoietin, EPO-bi and EPO-tetra, with different biological activities were isolated from the culture medium of a recombinant Chinese hamster ovary cell line, B8-300, into which the human erythropoietin gene had been introduced. EPO-bi, an unusual form, showed only one-seventh the in vivo activity and 3 times higher in vitro activity of the previously described recombinant human EPO (standard EPO). In contrast, EPO-tetra showed both in vivo and in vitro activities comparable to those of the standard EPO. EPO-bi, EPO-tetra, and the standard EPO had the same amino acid composition and immunoreactivity. However, structural analyses of their N-linked sugar chains revealed that EPO-bi contains the biantennary complex type as the major sugar chain, while EPO-tetra and the standard EPO contain the tetraantennary complex type as the major sugar chain. From examination of various preparations of recombinant human EPO, we found a positive correlation between the in vivo activity of EPO and the ratio of tetraantennary to biantennary oligosaccharides. These results suggest that higher branching of the N-linked sugar chains is essential for effective expression of in vivo biological activity of EPO.
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Human erythropoietin (EPO) is a glycoprotein hormone that plays a major role in regulating the level of circulating erythrocytes (1) by stimulating the maturation of late erythroid progenitor cells into proerythroblasts (2) . In the normal human adult, EPO is produced in the kidney (3) . EPO was first purified in a small amount from urine of aplastic anemia patients (4) . Several recombinant human EPOs produced in mammalian (5) (6) (7) (8) (9) and nonmammalian cells (10) have recently become available, but their biological activities differ from cell to cell. Since the structures of their polypeptide moieties are the same, such variation in activity was suspected as being due to the differences in their carbohydrate moieties. The sugar chain structures of urinary human EPO and recombinant human EPO produced in Chinese hamster ovary (CHO) cells were determined independently by us (11) and by Sasaki et al. (12) . Both urinary and recombinant human EPOs contain -40% carbohydrate in the form of three N-linked and one O-linked oligosaccharide chain. Important roles of the carbohydrate moiety in the solubility (13, 14) , biosynthesis (14) , and biological activity of EPO (9, 15) have been reported. Desialylation of EPO caused complete loss of its hormonal activity in vivo (15, 16) as the asialo-EPO was trapped in the liver (17) by the hepatic asialoglycoprotein binding protein (18) and was rapidly cleared from the circulation. Galactose oxidase treatment of asialo-EPO restored part of the biological activity (16) . These results suggested that EPO possesses full biological activity only when it is sufficiently sialylated to avoid clearance by the hepatic asialoglycoprotein binding protein. During the course of study of the productivity of EPO in several recombinant CHO cell lines, we found a unique cell line, B8-300, which produced an unusual form of EPO (EPO-bi) in addition to the usual form (EPO-tetra). EPO-bi showed very little in vivo activity, even though it had a sufficient amount of sialic acid to cover most of its galactose residues. This finding suggested that sugar moieties other than sialic acid residues might be important for the expression of in vivo EPO activity. Therefore, we made a comparative analysis of the sugar chain structures and the hormonal activities of several preparations of recombinant human EPO in order to understand the relationship between oligosaccharide structure and biological activity of this hormone.
MATERIALS AND METHODS
Reagents and Samples. All of the EPOs used in this study were produced by recombinant CHO cells, which carried a gene encoding human EPO, as described (19) and were purified from the culture medium by a series of chromatographic procedures (20) , including anion-exchange chromatography, reversed-phase chromatography, and gel filtration. In the case of EPO-bi, the reversed-phase chromatography step was not performed. The highly purified recombinant human EPO from a master cell line for which the N-linked sugar chains had been characterized (11) was used as a control and is called standard EPO in this paper. On an anion-exchange column, recombinant EPO produced by the B8-300 cell line was separated into two fractions: (i) EPOtetra eluted at the same salt concentration and pH as the standard EPO, and (ii) EPO-bi eluted at a lower pH when a solution of 5 mM acetic acid and 6 M urea (pH 4.7) was used. Hydrazine was purchased from Aldrich and redistilled to remove water completely. NaB3H4 (319.0 mCi/mmol; 1 Ci = 37 GBq) was purchased from New England Nuclear. Other reagents were purchased from Nacalai Tesque, Kyoto.
Assay. The protein content of EPO was measured by radioimmunoassay (21) with a rabbit polyclonal antibody raised against standard EPO and EPO labeled with 1251I by the chloramine-T method (22) . The in vitro and in vivo biological activities of the various recombinant human EPO preparations were assayed by incorporating 59Fe into rat bone marrow cells in culture (23) and into erythroblast cells of exhypoxic polycythemic mice (24) , respectively. The highly purified recombinant human EPO calibrated by the Second Abbreviations: EPO, erythropoietin; TN, total neutral oligosaccharides.
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International Reference Preparation was used as standard in all assays.
Sugar Chain Analysis. The structural analysis of sugar chains was carried out as described in our previous report (11) . Briefly, N-linked oligosaccharide chains of EPO were released from protein by hydrazinolysis and radiolabeled by NaB3H4 reduction (25) . The number of charges of the oligosaccharides was analyzed by FPLC using a Mono Q HR5/5 column (Pharmacia, Uppsala). The branching structures of the oligosaccharides were analyzed after desialylation with sialidase from Arthrobacter ureafaciens (Nacalai Tesque) by gel-permeation chromatography with Bio-Gel P-4 (-400 mesh; Bio-Rad) (26) .
RESULTS AND DISCUSSION
Structural Analysis of Sugar chains of EPO-bi and EPOtetra. The EPO-tetra showed in vivo specific activity comparable to that of the standard EPO, while the EPO-bi showed only one-seventh the in vivo specific activity of standard EPO (Table 1 ). In contrast, the specific activity obtained by an in vitro assay of EPO-bi was 3 times higher than that of the standard EPO. Both EPO-bi and EPO-tetra showed exactly the same amino acid compositions, while isoelectric focusing analysis indicated that EPO-bi contained a series of isoforms less negative than those found in EPOtetra and the standard EPO (data not shown). Then, we analyzed their N-linked sugar chains liberated by hydrazi- 20 30 eLution, min nolysis. When the released oligosaccharide mixtures were subjected to FPLC with a Mono Q column, they were separated into N, Al, A2, A3, and A4 with 0, 1, 2, 3, and 4 negative charges, respectively (Fig. 1) . The percent molar ratios of these fractions were as follows: 12, 22, 35, 22, and 9 in EPO-bi; 3, 10, 25, 32, and 30 in EPO-tetra. The values for standard EPO were 1, 14, 29, 33, and 23. As described in a previous report (11) , the acidic oligosaccharide fractions were almost completely converted by sialidase treatment to neutral ones (data not shown). Therefore, the difference in elution profiles of FPLC indicated that EPO-bi contains relatively less sialylated oligosaccharides than EPO-tetra or the standard EPO.
To analyze the neutral portions ofthe oligosaccharides, the asialo-oligosaccharides obtained by sialidase digestion ofAl, A2, A3, and A4 were combined with neutral oligosaccharides, and the total neutral oligosaccharides (TN) thus obtained were subjected to Bio-Gel P-4 column chromatography (Fig. 2) . The oligosaccharides from both EPO-bi ( Fig.  2A) and EPO-tetra (Fig. 2B) mented in the previous report (11) , each fraction was composed of biantennary (TN1), triantennary (TN2), or tetraantennary (TN3) oligosaccharides without and with one or two N-acetyllactosamine repeating units (TN4 and TN5, respectively), the structures of which are summarized in Fig. 3 . Thus, the data indicated that the EPO-bi fraction is enriched in biantennary oligosaccharide, while the EPO-tetra fraction and the standard EPO are enriched in tetraantennary oligosaccharides. Relationship Between Sugar Chain Structure and in Vivo Activity. As mentioned above, EPO-bi and EPO-tetra fractions differed in the extent of sialylation and branching of the complex-type N-linked sugar chains. To clarify whether these structural differences are related to differential in vivo activity, we purified several samples of recombinant human EPO with different in vivo activities from various lots of culture medium of a master cell line and analyzed their structures as described above.
Two major structural factors in the sugar chains could be considered as the basis of the difference in their biological activities. One is galactose exposure, and another is tetraantennary/biantennary oligosaccharide ratio. The former was considered because the hepatic asialoglycoprotein binding protein recognizes galactose residues at the nonreducing termini ofthe sugar chains ofEPO (11) . The latter was considered because of our finding that the branching structure appears to correlate with the in vivo activity of EPO. These two aspects were examined according to the following equations:
Galactose exposure (%) = (exposed galactose residues)/(exposed and sialylated galactose residues) x 100, = (exposed and sialylated galactose residues minus sialylated galactose residues)/(exposed and sialylated galactose residues) x 100, = [2 x TN1 + 3 x TN2 + 4 x (TN3 + TN4 + TN5) -(Al + 2 x A2 + 3 x A3 + 4 x A4)]/[2 x TN1 + 3 x TN2 + 4 x (TN3 + TN4 + TN5)] x 100.
Tetraantennary/biantennary oligosaccharide ratio = (TN3 + TN4 + TN5)/TN1 In the equations, the number of sialylated galactose residues was calculated from the contents of Al, A2, A3, and A4 separated upon FPLC with the use of the Mono Q column, which contains mono-, di-, tri-, and tetrasialylated oligosaccharides, respectively. Each of the antennae in an oligosaccharide has an exposed or sialylated galactose residue at its nonreducing terminus. Therefore, the total number of exposed and sialylated galactose residues is equivalent to the sum of all antennae, which can be calculated from the contents of bi-(TN1), tri-(TN2), and tetraantennary (TN3 + TN4 + TN5) oligosaccharides.
As shown in Fig. 4A , there was no correlation between galactose exposure and the in vivo activity of recombinant human EPO tested. In contrast, we found a positive relationship between the branching structure of sugar chains and the in vivo activity of EPO (Fig. 4B) . The in vivo activity of EPO was proportional to the ratio of tetraantennary to biantennary oligosaccharides with a correlation coefficient of 0.93. Some of the tetraantennary sugar chains (TN4 and TN5) contained N-acetyllactosamine repeating units, but their content was not correlated with the in vivo activity of EPO (data not shown).
These results indicate that EPO with biantennary sugar chains is less active in vivo and suggest that EPO with tetraantennary sugar chains should display its biological activity most efficiently under physiological conditions. Thus, the sugar chains of EPO seem to be important for the expression of its erythropoietic activity. In other words, the Gall-* 4GlcNAc1--2Manal>, 6 3Manl1-*4R, R' Galol-4GlcNAcol-o2Mana1l Galol-+4GlcNAcol'
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Gal1l-+4GlcNAcol-1 6Manl-+4R (14) , and (iv) activation of a biological response once bound to the receptor of target cells (29) . Removal of a glycosylation site by site-directed mutagenesis has been observed to impair the secretion of several glycoproteins (30, 31) , including EPO (14) .
The low in vivo activity of EPO-bi is not due to a defect in the activation of the biological response at the receptor level, since the EPO-bi demonstrated high activity in the in vitro assay. This is in contrast to the fact that deglycosylated forms of the pituitary and placental glycoprotein hormones cannot activate their target cells in vitro (29, 32, 33) . There may be a barrier against EPO-bearing small sugar chains on the way to the target tissue. The observation that the in vitro activity of EPO-bi is higher than that of the standard EPO is probably due to its lower overall charge (due to lower total sialic acid content), which might facilitate the approach to a receptor. This has been postulated for human lutropin and human chorionic gonadotropin (34) from the observations that their desialylated forms show increased binding to their target cells.
Several explanations can be made for the higher in vivo activity of human EPO-bearing tetraantennary oligosaccharide chains. The greater activity could be due to the larger size and/or greater total negative charge of the EPO-tetra lessening some nonspecific clearance mechanism such as filtration by the kidney or interaction with serum components such as proteases or binding proteins. Alternatively, the tetraantennary sugar chains could aid in the sequestration or retention of EPO in the target tissue through their structure, size, charge, or some specific interaction.
